Alector
$2.66
41
+$0.08+3.31% Today
Statistics
Day High
2.67
Day Low
2.58
52W High
3.32
52W Low
1.02
Volume
1,275,470
Avg. Volume
-
Mkt Cap
289.8M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
30JulExpected
Expected EPS
-0.2446
Actual EPS
N/A
Financials
-118.39%Profit Margin
Unprofitable201.12MRevenue
-238.1MNet Income
Analyst Ratings
6Average Price Target
The highest estimate is 6.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow ALEC. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap27.62B
Anavex Life Sciences
AVXL
Mkt Cap307.67M
AC Immune SA
ACIU
Mkt Cap303.29M
Prothena
PRTA
Mkt Cap580.86M
Ionis Pharmaceuticals
IONS
Mkt Cap12.44B
Alnylam Pharmaceuticals
ALNY
Mkt Cap39.51B
CRISPR Therapeutics
CRSP
Mkt Cap4.98B
Vertex Pharmaceuticals
VRTX
Mkt Cap107.83B
Novartis
NVS
Mkt Cap279.67B
About
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations. The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Alzheimer's disease and other tauopathies; ADP062-ABC, an alpha-synuclein siRNA for Parkinson's disease; and ADP065-ABC, an NLRP3 siRNA for neurodegenerative conditions. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including Latozinemab and Nivisnebart. The company was founded in 2013 and is headquartered in South San Francisco, California.
Show more...
CEO
Dr. Arnon Rosenthal Ph.D.
Employees
175
Country
United States
ISIN
US0144421072
Listings
0 Comments
Share your thoughts
FAQ
What is Alector stock price today?▼
The current price of ALEC is $2.66 USD — it has increased by +3.31% in the past 24 hours. Watch Alector stock price performance more closely on the chart.
What is Alector stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Alector stocks are traded under the ticker ALEC.
Is Alector stock price growing?▼
ALEC stock has risen by +13.26% compared to the previous week, the month change is a +11.09% rise, over the last year Alector has showed a +148.1% increase.
What is Alector market cap?▼
Today Alector has the market capitalization of 289.8M
When is the next Alector earnings date?▼
Alector is going to release the next earnings report on July 30, 2026.
What is Alector revenue for the last year?▼
Alector revenue for the last year amounts to 201.12M USD.
What is Alector net income for the last year?▼
ALEC net income for the last year is -238.1M USD.
How many employees does Alector have?▼
As of May 06, 2026, the company has 175 employees.
In which sector is Alector located?▼
Alector operates in the Health & Wellness sector.
When did Alector complete a stock split?▼
Alector has not had any recent stock splits.
Where is Alector headquartered?▼
Alector is headquartered in South San Francisco, United States.